Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1971 1
1977 1
1982 1
1985 2
1986 6
1987 2
1988 1
1989 6
1990 5
1991 4
1992 3
1993 3
1994 1
1995 4
1996 4
1997 2
1998 4
1999 12
2000 11
2001 10
2002 26
2003 36
2004 48
2005 61
2006 72
2007 84
2008 104
2009 119
2010 132
2011 178
2012 189
2013 209
2014 241
2015 274
2016 258
2017 226
2018 213
2019 227
2020 233
2021 251
2022 203
2023 182
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

3,313 results

Results by year

Filters applied: . Clear all
Page 1
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L.
LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK. LaFargue CJ, et al. Among authors: choi hj. Nat Commun. 2023 Apr 26;14(1):2407. doi: 10.1038/s41467-023-36910-5. Nat Commun. 2023. PMID: 37100807 Free PMC article.
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. Harding JJ, et al. Among authors: choi hj. Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2. Lancet Oncol. 2023. PMID: 37276871 Clinical Trial.
Wavelength-tunable spiral-phase-contrast imaging.
Lee DH, Lee S, Yeo WJ, Jeong SK, Jeon M, Choi HJ, Kim HS, Bae JY, Kim DU, Hur H, Hyun S, Lee KS, Chang KS, Lee W, Pak S, Kim GH, Kim IJ. Lee DH, et al. Among authors: choi hj. Opt Express. 2022 Jul 18;30(15):27273-27284. doi: 10.1364/OE.461660. Opt Express. 2022. PMID: 36236901 Free article.
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Lee CK, et al. Among authors: choi hj. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65. doi: 10.1016/S2468-1253(22)00335-1. Epub 2022 Oct 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36328033 Clinical Trial.
Korean guidelines for the management of gout.
Lee JJ, Lee JS, Chung MK, Ahn JK, Choi HJ, Hong SJ, Yoon CH, Kim SH, Jeong KH, Kim JW, Kim BY, Shin JH, Kim WG, Kim SY, Kim HJ, Song JS, Jun JB, Park HA, Chae SC, Choi BS, Kim TN, Kim HA. Lee JJ, et al. Among authors: choi hj. J Rheum Dis. 2023 Jul 1;30(3):141-150. doi: 10.4078/jrd.2023.0029. J Rheum Dis. 2023. PMID: 37476677 Free PMC article. Review.
ER stress: an emerging regulator in GVHD development.
Choi HJ, Yu XZ. Choi HJ, et al. Front Immunol. 2023 Sep 6;14:1212215. doi: 10.3389/fimmu.2023.1212215. eCollection 2023. Front Immunol. 2023. PMID: 37744326 Free PMC article. Review.
3,313 results